3 research outputs found
Isolation, Structure Determination, and Anti-HIV Evaluation of Tigliane-Type Diterpenes and Biflavonoid from <i>Stellera chamaejasme</i>
Five novel tigliane-type diterpenes,
stelleracins A–E (<b>3</b>–<b>7</b>), a
novel flavanone dimer, chamaeflavone
A (<b>8</b>), and six known compounds were isolated from the
roots of <i>Stellera chamaejasme</i>. Their structures were
elucidated by extensive spectroscopic analyses. The isolated compounds
were evaluated for anti-HIV activity in MT4 cells. New compounds <b>3</b>–<b>5</b> showed potent anti-HIV activity (EC<sub>90</sub> 0.00056–0.0068 μM) and relatively low or no
cytotoxicity (IC<sub>50</sub> 4.4–17.2 μM). These new
compounds represent promising new leads for development into anti-AIDS
clinical trial candidates
Isolation, Structure Determination, and Anti-HIV Evaluation of Tigliane-Type Diterpenes and Biflavonoid from <i>Stellera chamaejasme</i>
Five novel tigliane-type diterpenes,
stelleracins A–E (<b>3</b>–<b>7</b>), a
novel flavanone dimer, chamaeflavone
A (<b>8</b>), and six known compounds were isolated from the
roots of <i>Stellera chamaejasme</i>. Their structures were
elucidated by extensive spectroscopic analyses. The isolated compounds
were evaluated for anti-HIV activity in MT4 cells. New compounds <b>3</b>–<b>5</b> showed potent anti-HIV activity (EC<sub>90</sub> 0.00056–0.0068 μM) and relatively low or no
cytotoxicity (IC<sub>50</sub> 4.4–17.2 μM). These new
compounds represent promising new leads for development into anti-AIDS
clinical trial candidates
Carbamoyl Pyridone HIV‑1 Integrase Inhibitors 3. A Diastereomeric Approach to Chiral Nonracemic Tricyclic Ring Systems and the Discovery of Dolutegravir (S/GSK1349572) and (S/GSK1265744)
We report herein the discovery of
the human immunodeficiency virus type-1 (HIV-1) integrase inhibitors
dolutegravir (S/GSK1349572) (<b>3</b>) and S/GSK1265744 (<b>4</b>). These drugs stem from a series of carbamoyl pyridone analogues
designed using a two-metal chelation model of the integrase catalytic
active site. Structure–activity studies evolved a tricyclic
series of carbamoyl pyridines that demonstrated properties indicative
of once-daily dosing and superior potency against resistant viral
strains. An inherent hemiaminal ring fusion stereocenter within the
tricyclic carbamoyl pyridone scaffold led to a critical substrate
controlled diastereoselective synthetic strategy whereby chiral information
from small readily available amino alcohols was employed to control
relative and absolute stereochemistry of the final drug candidates.
Modest to extremely high levels of stereochemical control were observed
depending on ring size and position of the stereocenter. This approach
resulted in the discovery of <b>3</b> and <b>4</b>, which
are currently in clinical development